Tashkent hosted a satellite symposium “New Possibilities of IHD Therapy” organized by “Les Laboratoires SERVIER” Pharmaceutical Company – key partner of the congress – within the frameworks of the VII Eurasian Congress of Cardiology. Medical Express Journal was an information partner of the congress and symposium.             Preventive and Emergency Cardiology Chair Professor, Department for Postgraduate Continuous Education (DPCE), I.A. Sechenov Moscow Medical Academy (Sechenov MMA), Head of Laboratory for Functional Testing Methodology and Prudent Pharmacotherapy of Cardiovascular Diseases, Sechenov MMA and Municipal Clinical Hospital No. 59, Professor Maria G. Glezer, Doctor of Medical Science. New Possibilities of IHD Therapy  А link to the video (Russian version) Professor Maria G. Glezer presented evidence-based information about a ischemic heart disease (coronary artery disease) case management strategy, prevention of complications, improvements of outcomes, elimination or mitigation of angina pectoris and myocardial ischemia as well as improvements in patients’ quality of life. Discussed issues concerned pharmacological therapy for improvement of treatment outcomes and necessary interventions to achieve blood pressure normalization. An ODA National Multicenter Observation Program to assess the efficacy and therapeutic response to daily practical use of Preductal OD 80 mg for treatment of stable angina pectoris was presented.  Therapy aimed at correction of changes in energy metabolism, which is essential in case of ischemia, was described because it prevents initial stages of myocardial cell damage.               Junior Research Associate, Laboratory of IHD and Atherosclerosis, Republican Specialized Scientific and Practical Medical Center of Cardiology, Winner of 2016 Contest of Young Scholars. Nizamov, U. I. (Tashkent, Uzbekistan). Contemporary Dimensions of Anti-ischemic Therapy. Clinical Case Study А link to the video (Russian version) The presentation focused on ischemic heart disease (coronary artery disease) with emphasis anti-ischemic therapy using the example from a specific case. The presenter introduced a strategy for management of these cases. The speaker stressed the importance of reviewing a combination of anti-ischemic medications, which influence the treatment outcome in such patients and assessing the risk stratification for conducting revasculation. Medical Express Correspondent Medical Express Photo and Video Reporter                                                                                                                                                                                                                                                                    

AN INTERDISCIPLINARY PLATFORM FOR DISCUSSION OF OPTIMAL MANAGEMENT OF MULTIMORBID PATIENTS IN THE AREA OF CARDIOLOGY, NEPHROLOGY AND DIABETES “ARTERIAL HYPERTENSION AND COMORBID CONDITIONS: UPDATES ON APPROACHES TO DIAGNOSTICS AND TREATMENT ON THE BASIS OF RECOMMENDATIONS” On 9 November 2018, Tashkent, Uzbekistan, hosted a Cardio Forum 2018. As many as 670 doctors from Tashkent and the regions took part in the forum. This large-scale event held under the aegis of the Association of Cardiologists of Uzbekistan and European Society of Cardiology in close cooperation with Berlin-Chemie/Menarini Company.               Academician R. Kurbanov, addressed the participants with welcoming words at the Forum opening ceremony and underscored the high relevance of hypertention treatment, especially, the high incidence of comorbid conditions: diabetes mellitus, metabolic syndrome, CRD, COPD, cerebrovascular diseases and others, which affect the course, nature and severity of complications, which frequently obscure diagnostics, and, indeed, determine specifics in choosing antihypertensive medications. In this context, cardiologists require extensive knowledge of concomitant diseases with the view of preventing a risk for development of life-threatening complications.               Professor Athanasios J. Manolis (Greece), the President and General Secretary of the Mediterranean Association of Cardiology and Cardiosurgery, delivered a presentation “Arterial Hypertension: A Critical Approach of the Recently Published ESC/ESH and ACC/AHA Guidelines” . a link to the video               A presentation on “Control of Heart Rate and Blood Pressure” was made by Deputy Director for Science, Republican Specialized Center for Cardiology (RSCC) of the Republic of Uzbekistan, Doctor of Medical Sciences, Professor Shek A.B.                  Professor G. Khamidullaeva, Doctor of Medical Sciences, Head of the Department of Arterial Hypertension, RSCC of the Republic of Uzbekistan, gave a presentation “Treatment of Arterial Hypertension in Chronic Renal Disease”.                                  Professor Jan T. Kielstein  (Germany) - a leading expert in therapy of renal diseases and arterial hypertension, cardiovascular risk in patients on dialysis at the Center for Cardiovascular Research at Blood Purification  Academic Teaching Hospital Braunschweig - spoke about “Hyperuricaemia - an Update in its Role in CV and Renal Disease”. a link to the video               Clinical case studies, robust discussions, a great number of questions to the presenters made the Forum relevant and meaningful for all the participants, which, undoubtedly will serve as the groundwork for improvements in care for thousands of patients and reduction in the risk of cardiovascular complications.a link to the video               “Medical Express” correspondent “Medical Express” photo and video reporter                    

“BIONORICA SE” Pharmaceutical Company’s CEO and  Chairman of the Executive Board, Professor Michael A. Popp, gave an exclusive interview to “Medical Express” Journal about effective treatment methods using innovative plant-based medicines presented at the Fifth Congress of Urologists in Uzbekistan and noted that Uzbekistan is a unique country with remarkable potential for scientific research. — Professor Popp, how does “BIONORICA SE” manage to effectively combine centuries-old knowledge with current achievements of scientific and technological progress? — “BIONORICA SE” uses the knowledge of history and empirical knowledge passed on by my grandfather to my father, who was also a physician specializing in research and production of plant-based medicines. At the same time, extensive experience of physicians including urologists underlies our developments. In combination, this enabled us to devise a completely new approach to using plant-based medicines. We think about how we can do the best state-of-the art modern science, we develop clinical protocols and conduct clinical studies with our products and we are very happy that at the end we succeed. We can show, for example, that our Canephron is as good as Fosfomicin in a patient with an uncomplicated urinary tract infection without the use of antibiotic in the first line. In almost 84% of monotherapy, our plant-based medicine was sufficient and female patients did not need an additional antibiotic leading to a high successful treatment rate, which was, in principle, impossible in the past. However, this success requires a lot of money and a lot of trust and belief in your product.    — The Fifth Convention of Urologists of Uzbekistan is taking place today. Developments regarding which medicine did “BIONORICA SE” present to the participants of this scientific forum? — One of key areas that we are exploring and presenting within our production are plant-based medicines. It is very important that you have the best raw materials. It means you have to take a lot of efforts to ensure constant homogenous quality of the product. It is important for each natural product to have the best quality of raw materials. Then, you need the best way of production, a modern way of production, to produce a good plant-based herbal medicine. Today, we presented Canephron that enabled us to show our newest developments. The newest developments show how Canephron works pharmacologically. It is important to point out that findings of clinical studies proved the effectiveness of this medication in treatment of uncomplicated urinary tract infections. We have currently proven that Canephron acts as good as Fosfomicin in cases of uncomplicated urinary tract infection. It is important because antimicrobial resistance of pathogens to various antibiotics, which eventually stop to work, is a problem that is so huge that even the World Health Organization focuses on it. — Dr. Popp, you've been coming for more than 10 years to Uzbekistan, could you, please, share your impressions? — About 10 лет years ago, I was fortunate to visit your country and back then I was astonished with the organization of the forum that took place in Tashkent and we were connect by video with doctors in Samarkand, Khiva and other cities and it worked. Today, I was pleasantly surprised to learn about two innovations – a questionnaire for acute cystitis developed in Uzbekistan and translated into 19 world languages and internationally validated, which we use in our scientific research. Secondly, a unique patient registration system was introduced in Uzbekistan and being introduced in several other countries. Today, I am convinced once again that Uzbekistan is a unique country with remarkable potential for scientific research.   “Medical Express” correspondent “Medical Express” photo and video reporter                                                                                                            

Tashkent hosted the Fifth Congress of Urologists in Uzbekistan with international participation entitled “Modern Technologies in Diagnostics and Therapy of Urological Diseases”. The event was organized by the Ministry of Health of the Republic of Uzbekistan and the Society of Urologists of the Republic of Uzbekistan. “Medical Express” Journal had a role of an information partner of the congress.                   The congress agenda included 6 plenary sessions dedicated to modern global achievements in urology. Deputy Minister of Health of the Republic of Uzbekistan, Professor A. M. Khadjibayev, opened the congress. The Head of Uzbekistan’s Society of Urologists, Doctor of Medical Sciences, Professor Farkhad Akilov, and Director of the Republican Specialized Scientific and Practical Medical Center for Urology, Chief Urology Consultant to the Ministry of Health of the Republic of Uzbekistan, Doctor of Medical Sciences, Professor Sh. Mukhtarov addressed the participants of the congress with welcoming remarks. Leading urologists from Germany, Georgia, Kazakhstan, Russia, the United States of America, Tajikistan, Turkey and Uzbekistan attended the congress. Professor Michael Popp (Germany) made a presentation on “The phytoneering principle: Researched phytomedicines in times of growing antibiotic resistance”.             A presentation "Do we Need Always Antibiotic Therapy to Treat Uncomplicated Cystitis? New Aspects from Guidelines" was delivered by Professor Kurt G. Naber (Germany).           Professor Bj?rn Wullt (Sweden) made a presentation on “Bacteria and Host Interaction in UTI with New Perspectives on Non-antibiotic Treatments”.           A presentation “"Change of a Paradigm in UTI: quo vadis?" was delivered by Professor Florian M. Wagenlehner (Germany).              Dr. Jakhongir Alidjanov presented “Aspects of Symptom-based Diagnostics of the Lower UTI”. Other plenary sessions including “Modern Technologies in Urology”, “Modern Diagnostics and Therapy of Lower Urinary Tract Symptoms”, and “Modern Aspects of Men’s Health” were also organized for the participants of the congress. “Medical Express” correspondent. “Medical Express” photo and video reporter.?                                                                                                                                                                                                                                                                                                  

  During the days of the Fifth Congress of Urologists of Uzbekistan, the Chairman of the Board and Owner of “BIONORICA SE” Company, Professor Michael Popp, visited a Psychoneurological Clinic named after Kurbanov for treatment and rehabilitation of children afflicted with infantile cerebral palsy. For more than a decade, ill children from Germany, Uzbekistan and other countries have been receiving assistance from Natureheart Charity Foundation (previously known as Phytokids and Leon Heart Foundation) established upon the initiative of Professor Michael Popp. Within these frameworks, regular joint charity events have been organized for children at this Tashkent-based hospital in collaboration with the Ministry of Health of the Republic of Uzbekistan since 2011.                   Uzbek-German humanitarian collaboration along these lines resulted in setting up a rehabilitation playroom “Phytoland” in 2011 at the clinic named after Kurbanov followed by opening a sensory room in 2012 – a specially equipped room designed for therapeutic and rehabilitation sessions for children with deviations in their development, and installation of an X-ray machine in 2013, renovation and launching of two classrooms in 2016, and a computer class that was opened in 2017 and equipped with a sensory board and latest computers to give a child with mobility impairments a chance in the future, which he or she did not have previously, to engage into highly skilled and high-paying work and send it to employers electronically via e-mail and feel like everybody else. During the visit, Professor Michael Popp discussed prospects of organizing future charity events and was informed about the operation of children’s rooms and classrooms created by the foundation and about how the previously provided equipment had been used. A concert with participation of little patients of the clinic was organized to honour his visit. All children received gifts and books.                   A sensory room is a specially equipped room designed for therapeutic and preventive  sessions necessary for children with deviations in their development THE HISTORY OF ORGANIZING CHARITY EVENTS FOR CHILDREN. FROM PHYTOKIDS AND LEON HEART FOUNDATION TO NATUREHEART FOUNDATION Besides production and research of phytomedicines, “Bionorica SE” also conducts charity events for children. In 2007, Professor Michael Popp – the owner of the company – set up the Phytokids Charity Fund, which received a new name Leon Heart Foundation in 2015. A lion is symbol of protection of children and embodies the purpose of the foundation: “Children fight as lions to achieve good health. And the foundation will also fight like a lion to create better life for children,” – explained Professor Michael Popp. The Leon Heart Foundation has been recently renamed into Natureheart Foundation for Kids. The foundation has been renamed to reflect its restructuring. The overarching goal of the foundation is still about helping children and adolescents at social care and health care institutions in Germany and many other countries around the world. Reorientation of the groundwork and subsequent renaming are related, in no small measure, to a socially significant antibiotic resistance theme. Excessively frequent and inappropriate use of antibiotics results in increased risks for microbioms, i.e., microbiological diversity in a human body. “Here, we intend to bring the power of nature closer to children and their parents and send a clear message that in most areas of use there are effective alternative medicines or therapeutic concepts that are natural, based on plants,” – says Professor Michael Popp. Relevant scientific education is one of the central objectives of the new foundation for children of nature. “Medical Express” correspondent  “Medical Express” photo and video reporter                   A concert with participation of little patients of the clinic was organized in honour of the visit of Chairman of the Board and Owner of “BIONORICA SE” Company, Professor Michael Popp                 A computer class equipped with a sensory board and latest computers                                                                                                                                                                      

  26th Congress of the European Psychiatric Association (EPA) — the largest International Psychiatric Association — took place on 3-6 March 2018 at Nice Acropolis Convention Centre (France). Delegations of psychiatrists from more than 50 countries took part in the Congress. The organisers expressed the theme of the congress in a slogan «Mental Health - Integrate, Innovate, Individualise». The Congress of the European Psychiatric Association brought together expert clinicians, researchers and leaders of stakeholder organisations in the field of mental health. The Congress agenda included plenary sessions, lectures, and satellite symposia dedicated to highly relevant areas in the development of psychiatry, educational courses, workshops, informal meetings with experts and sessions designed for early career psychiatrists. Pharmaceutical Company «Gedeon Richter» (Hungary) participated as a scientific partner in the Congress. An innovative medication Reagila (cariprazine) of Pharmaceutical Company «Gedeon Richter » (Hungary) was presented during the Congress days as an antipsychotic to be used in adult patients with schizophrenia.  This medication is a dopamine D3/D2 receptor partial agonist. A satellite symposium entitled «Past, Present and Future of Schizophrenia Negative Symptoms Treatment» was held where three presenters from different parts of the world gave their  speeches. The symposium was chaired by Prof. Istvan Bitter (Hungary), a Professor of Department of Psychiatry and Psychotherapy at Semmelweis University in Budapest, Hungary, who introduced the three presenters that highlighted topical aspects of this problems and treatment methods using the latest interventions. It was pointed out that negative symptoms of schizophrenia have a significant impact on day-to-day functioning of patients and constitute a main barrier to an acceptable quality of life. Antipsychotics are effective in the treatment of positive symptoms, but treatment of schizophrenia with negative symptoms remains a clinical challenge. Schizophrenia negative symptoms: a burden for patients, caregivers and society a link to the video The President of the European Psychiatric Association, Prof. Silvana Galderisi (Italy), Professor of Psychiatry at the University of Campania Luigi Vanvitelli, Italy, gave a speech at this satellite symposium on «Schizophrenia negative symptoms: a burden for patients, caregivers and society» where she summarised the unmet needs of people with schizophrenia, and described the burden of negative symptoms on users, caregivers and overall society. Dopamine receptors remain a valid target for effective treatment of schizophrenia a link to the video Two more presenters spoke at this symposium. In the second lecture, Prof. Leslie Citrome (USA), a Clinical Professor of Psychiatry & Behavioral Sciences at New York Medical College in Valhalla, NY with private practice in Pomona, NY, USA, entitled «Dopamine receptors remain a valid target for effective treatment of schizophrenia » gave an overview on the features, similarities and differences of atypical antipsychotics, especially the dopamine receptor partial antagonists («ABC»-drugs), namely, aripiprazole, brexpiprazole and cariprazine. Treatment of schizophrenia negative symptoms: Do we have an adequate solution? Prof. Stefan Leucht (Germany) Deputy Director of the Department of Psychiatry and Psychotherapy of the Technische Universität München, Munich, Germany, gave the third lecture «Treatment of schizophrenia negative symptoms: Do we have an adequate solution?» where he presented clinical study data on different negative symptom antipsychotic symptom trials, analyzing also the gained data with cariprazine. Abstracts of the Congress can be accessed at http://www.epa-congress.org/2018/programme-submission/abstract-book-2018#.Wp57ZmrOXX4 Further information about ЕРА-2018 and ЕРА-2019 is available at www.epa-congress.org  The report was prepared by R. Ribnikov. Photos and videos by correspondents of International Medical Journal & Association «Medical Express» for Physicians. Nice, France. March 2018.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       26th Congress of the European Psychiatric Association (EPA) — the largest International Psychiatric Association — took place on 3-6 March 2018 at Nice Acropolis Convention Centre (France). Delegations of psychiatrists from more than 50 countries took part in the Congress. The organisers expressed the theme of the congress in a slogan «Mental Health - Integrate, Innovate, Individualise». The Congress of the European Psychiatric Association brought together expert clinicians, researchers and leaders of stakeholder organisations in the field of mental health. The Congress agenda included plenary sessions, lectures, and satellite symposia dedicated to highly relevant areas in the development of psychiatry, educational courses, workshops, informal meetings with experts and sessions designed for early career psychiatrists. Pharmaceutical Company «Gedeon Richter» (Hungary) participated as a scientific partner in the Congress. An innovative medication Reagila (cariprazine) of Pharmaceutical Company «Gedeon Richter » (Hungary) was presented during the Congress days as an antipsychotic to be used in adult patients with schizophrenia.  This medication is a dopamine D3/D2 receptor partial agonist. A satellite symposium entitled «Past, Present and Future of Schizophrenia Negative Symptoms Treatment» was held where three presenters from different parts of the world gave their  speeches. The symposium was chaired by Prof. Istvan Bitter (Hungary), a Professor of Department of Psychiatry and Psychotherapy at Semmelweis University in Budapest, Hungary, who introduced the three presenters that highlighted topical aspects of this problems and treatment methods using the latest interventions. It was pointed out that negative symptoms of schizophrenia have a significant impact on day-to-day functioning of patients and constitute a main barrier to an acceptable quality of life. Antipsychotics are effective in the treatment of positive symptoms, but treatment of schizophrenia with negative symptoms remains a clinical challenge. Schizophrenia negative symptoms: a burden for patients, caregivers and society a link to the video The President of the European Psychiatric Association, Prof. Silvana Galderisi (Italy), Professor of Psychiatry at the University of Campania Luigi Vanvitelli, Italy, gave a speech at this satellite symposium on «Schizophrenia negative symptoms: a burden for patients, caregivers and society» where she summarised the unmet needs of people with schizophrenia, and described the burden of negative symptoms on users, caregivers and overall society. Dopamine receptors remain a valid target for effective treatment of schizophrenia a link to the video Two more presenters spoke at this symposium. In the second lecture, Prof. Leslie Citrome (USA), a Clinical Professor of Psychiatry & Behavioral Sciences at New York Medical College in Valhalla, NY with private practice in Pomona, NY, USA, entitled «Dopamine receptors remain a valid target for effective treatment of schizophrenia » gave an overview on the features, similarities and differences of atypical antipsychotics, especially the dopamine receptor partial antagonists («ABC»-drugs), namely, aripiprazole, brexpiprazole and cariprazine. Treatment of schizophrenia negative symptoms: Do we have an adequate solution? Prof. Stefan Leucht (Germany) Deputy Director of the Department of Psychiatry and Psychotherapy of the Technische Universität München, Munich, Germany, gave the third lecture «Treatment of schizophrenia negative symptoms: Do we have an adequate solution?» where he presented clinical study data on different negative symptom antipsychotic symptom trials, analyzing also the gained data with cariprazine. Abstracts of the Congress can be accessed at http://www.epa-congress.org/2018/programme-submission/abstract-book-2018#.Wp57ZmrOXX4 Further information about ЕРА-2018 and ЕРА-2019 is available at www.epa-congress.org  The report was prepared by R. Ribnikov. Photos and videos by correspondents of International Medical Journal & Association «Medical Express» for Physicians. Nice, France. March 2018.